Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. - Wikidata - wikimedia - TriplyDB

Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.

Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.

http://www.wikidata.org/entity/Q30843481

about

Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine.Biophysical Properties and Motility of Human Mature Dendritic Cells Deteriorated by Vascular Endothelial Growth Factor through Cytoskeleton Remodeling.Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity.Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.Shaping of Peripheral T Cell Responses by Lymphatic Endothelial Cells.In Vivo Imaging Sheds Light on Immune Cell Migration and Function in Cancer.Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.Cancer Immunotherapy: Whence and Whither.Dendritic cells in cancer: the role revisited.Functions of Murine Dendritic Cells.Dendritic Cells and Cancer Immunity.TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines Lymphatic Vessels Balance Viral Dissemination and Immune Activation following Cutaneous Viral Infection Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response.Antigen Cross-Presentation and T-Cell Cross-Priming In Cancer Immunology And Immunotherapy.Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.FOXOs in Cancer Immunity: Knowns and Unknowns.Informatics for cancer immunotherapy.Targeting tumor microenvironment to curb chemoresistance via novel drug delivery strategies.Integration of nano drug-delivery system with cancer immunotherapy.Toll-like receptor 3 signal augments radiation-induced tumor growth retardation in a murine model.Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models.Innate and acquired immune surveillance in the postdissemination phase of metastasis.NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy.Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses.Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity.Understanding the tumor immune microenvironment (TIME) for effective therapy.Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy.Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma.Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer.CD103+ cells at the forefront of anticancer immunity.β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.Approaches to Improve Chemically Defined Synthetic Peptide Vaccines.Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer.

P2860

Q30830664-93BD785C-5A52-4968-AA20-C86D436CED93 Q36181047-E8B0C96A-312A-4B25-B3E4-79AA3AC7EC4E Q37473978-D2A65CAE-F535-416F-86B4-C3C2EDABB5C4 Q37541609-738299E3-9A89-4569-ACFE-751EE72A5ECA Q37554718-85E82E6B-7750-4731-A9E1-403BA1196C2E Q37580778-F83B9BBE-CB57-4585-A630-59B53626CE3A Q37714428-03AA6A0E-EF9E-4C08-8066-8B1A0EE239E0 Q38704192-CC14416C-05D1-42E7-9344-87B027BFE533 Q38737924-673F0097-8D79-4999-A478-F2F7D467A90F Q38963934-AA4EBB1F-53FF-4A15-9858-795B9F34EB3D Q38985483-B085F75F-9C5B-4F06-888A-CD11BC9EF157 Q38994017-18FF3E6F-6BAA-4F59-AF55-658B8C287B61 Q39160959-8D4DF62B-800C-4E49-A01A-217B8743F316 Q39448911-7B903F38-A901-4671-91AD-A0094776196D Q41664330-A349F4F5-EDBE-4B2C-9DBF-8F4D13321F4F Q41693862-558DDB7C-9F33-4216-9A2F-6EB702A56B76 Q41718028-B7553594-3BA4-4C56-ADE6-D9EBE81EEF09 Q41930681-8118BED6-A446-4938-8B88-3809D20AB637 Q42378527-2F1A8D74-9351-4459-95FA-8A17ED5F142F Q47134263-7D6330B3-A877-4D30-BB15-BB6C173022A0 Q47224295-DA80E622-22D9-4431-80BD-7E303DD1492C Q47290509-30D153B0-1DE5-43FB-A220-3C54107FD0D1 Q48308048-37291FB2-EAC7-4CC4-A46A-495F5E4C5D8A Q48622958-30879DBF-B5B2-4EBF-BAC5-FBE592E55C4E Q49710218-253D2211-EC0C-4714-9D98-FE1B6E09333F Q49737040-00C0E04C-219F-4B08-90F2-921DD45B26C6 Q50048813-F154E916-DB50-4708-87BD-77E93CC35B32 Q50076191-685FA5B5-3291-491E-9564-2F084FA5BFC1 Q50420406-68B71EAA-8E0B-4297-8466-E3FEC8667547 Q50647447-EA489D27-9017-4941-9128-005C4A044EC6 Q50676824-C960755F-D869-4820-B920-BAB77391F3AA Q52311744-4C9A3967-61CF-49EC-BD25-AB70D0EAE6BD Q52606149-A60994C1-CF2D-47D6-92E5-407CF9E2C59A Q52720866-7D3DA09B-3EE0-4B1D-AAB2-07AB8A889D2E Q52723482-2E91C19F-79ED-4099-8218-F37D83999568 Q52726024-80254B10-DA90-467C-BC74-EE658CA17C08 Q52780158-40B2C151-6010-465B-8005-09FA34E0317B Q52801913-530A6D16-E727-407E-8D92-8A429D727185 Q54961397-88715F63-DAF9-45C2-BB35-544053E31DF4 Q54977101-95FE8380-9DFF-4BEB-87DB-45064E66EC14

P2860

Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.

http://www.wikidata.org/entity/Q30843481

description

2016 nî lūn-bûn

@nan

2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Critical Role for CD103(+)/CD1 ...... f T Cell Immunity in Melanoma.

@ast

Critical Role for CD103(+)/CD1 ...... f T Cell Immunity in Melanoma.

@en

type

label

Critical Role for CD103(+)/CD1 ...... f T Cell Immunity in Melanoma.

@ast

Critical Role for CD103(+)/CD1 ...... f T Cell Immunity in Melanoma.

@en

prefLabel

Critical Role for CD103(+)/CD1 ...... f T Cell Immunity in Melanoma.

@ast

Critical Role for CD103(+)/CD1 ...... f T Cell Immunity in Melanoma.

@en

P1433

Q30843481-D328D65C-2AA0-4648-9DB8-6CA8F31FF02E

P1476

Q30843481-1733D090-1E55-4477-A33F-A74B314B5692

P2093

Q30843481-085064C6-3242-445F-B889-55D4DC3AE4AE

Q30843481-4369077A-1E3C-4A68-8A04-AF4718C6871B

Q30843481-4D7A694C-BAAF-4592-A442-FD7756DDB194

Q30843481-5A2DF400-494D-4289-9C1F-4E3ACE1817A5

Q30843481-772DDFA9-E176-4ED8-9E7F-9E91E58FBF4C

Q30843481-80DFB7B2-E776-4AB2-8FDD-DE80C274A261

Q30843481-92541F01-AC30-4B79-BEF0-6ADB11602D19

Q30843481-D86C065D-8405-414F-93F7-7451780E82C6

P2860

Q30843481-08E8FC52-5E64-4E9D-992B-51766362C586

Q30843481-21030205-EE1B-446F-862A-BD1819D5DCEF

Q30843481-22BD305C-F7EE-4780-AB7D-D518918F1377

Q30843481-3992C4BF-19C9-4855-AAC8-6728A15E73A5

Q30843481-40F5283F-62B7-409D-9559-AD67ED2C9E01

Q30843481-4DA1CAF5-1695-4A08-8455-0D74E2D06189

Q30843481-4EC7B892-29DC-4B68-97FC-0A5A830E7158

Q30843481-515ED1DC-19FA-4ADC-8821-415C96C27540

Q30843481-5FFDEE72-C81D-41D8-A358-558AC5F37F6A

Q30843481-6945B954-D943-4F75-963D-D078841736B7

P304

Q30843481-05BB16DE-2D1B-4D9E-85B8-617E78E01797

P31

Q30843481-0A0D6456-4500-45DA-900B-CE1D02E41FCD

P356

Q30843481-E7DD28B3-EDB1-420A-B643-E9310DC91B09

P433

Q30843481-A2EC8D07-CFA0-4A98-A318-205FCF1504AC

P478

Q30843481-C64D01CC-6AAB-4A02-975D-3F27FF07CD22

P50

Q30843481-A22A8EA4-A76F-4173-A382-886F73B38E1F

Q30843481-EFCCFA74-36FA-4731-BA08-7E8A191B809E

P577

Q30843481-0ADAA03A-F551-40AA-ABCF-8D5E065C01C9

P698

Q30843481-32806DC0-5B1D-463D-870E-3F820D0F4380

P932

Q30843481-FC381933-2F73-40D0-B307-452DFCF7F42A

P356

J.CCELL.2016.06.003

P1433

P1476

Critical Role for CD103(+)/CD1 ...... f T Cell Immunity in Melanoma.

@en

P2093

Amanda E Nelson

http://www.w3.org/2001/XMLSchema#string

Denise M Wolf

http://www.w3.org/2001/XMLSchema#string

Dusan Bogunovic

http://www.w3.org/2001/XMLSchema#string

Matthew F Krummel

http://www.w3.org/2001/XMLSchema#string

Mikhail Binnewies

http://www.w3.org/2001/XMLSchema#string

Miranda L Broz

http://www.w3.org/2001/XMLSchema#string

Nina Bhardwaj

http://www.w3.org/2001/XMLSchema#string

Tsuneyasu Kaisho

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

Innate and adaptive immune cells in the tumor microenvironment

Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity

The blockade of immune checkpoints in cancer immunotherapy

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss

Tyrosine kinase receptor RET is a key regulator of Peyer's patch organogenesis

Bright fluorescence monitoring system utilizing Zoanthus sp. green fluorescent protein (ZsGreen) for human G-protein-coupled receptor signaling in microbial yeast cells

P304

324-336

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCELL.2016.06.003

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Edward W Roberts

P577

2016-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27424807

http://www.w3.org/2001/XMLSchema#string

P932

5374862

http://www.w3.org/2001/XMLSchema#string